Floatz logo

Jcar017 (Lisocabtagene Maraleucel)

Leukemia, Lymphocytic, Chronic, B-Cell

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyCell therapyPhase 3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

71 Active assets in the Leukemia, Lymphocytic, Chronic, B-Cell cohort.

Asset / SponsorPhaseRating
Humax-Cd20
Emory University
Phase 4BBB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
Acalabrutinib
Zulfa Omer
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Jcar017 (Lisocabtagene Maraleucel) is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →